// App-Quantinova.ai

3331 : RP6530, a dual PI3K / inhibitor attenuates cancer stem cell proliferation in serous adenocarcinoma of ovary

Researchers

Presenter

  • Sneha S

Principal Investigators

  • Nivetha R

  • Srikant Viswanadha

  • Swaroop Vakkalanka

  • Ganesan TS

Medical Centers

  • Cancer Institute (W.I.A), Chennai, India

  • Incozen Therapeutics Pvt. Ltd., Shameerpet Hyderabad, India

  • Rhizen Pharmaceuticals SA, Chennai, Switzerland.

Locations

  • India

  • Switzerland

Companies

  • Incozen Therapeutics

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Ovarian cancer

  • Hematological malignancies

  • Gynaecological cancer

  • Solid malignancies

Biomarkers

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

Drug/Treatment

  • RP6530

Outcome

  • N/A

Study Design

  • Dose Escalation

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved